Results 181 to 190 of about 510,210 (307)

Urothelial Bladder Cancer With Cardiac Metastasis: A Case Report. [PDF]

Cureus
Bounouar O, El Moudane A, Andrea E, Jdaini A, Barki A.   +4 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Testosterone replacement therapy and bladder cancer. [PDF]

Can Urol Assoc J
Kanaan MF, Breau RH, Lavallée LT, McIsaac DI, Witherspoon L.   +4 more
europepmc   +1 more source

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source

ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer. [PDF]

Front Oncol
Bajdak-Rusinek K, Jankowska K, Sundararajan V, Sieroń Ł, Diak N, Wójtowicz W, Stępień KL, Fus-Kujawa A, Gutmajster E, Wierzbinka M, Zorychta K.   +10 more
europepmc   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells". [PDF]

Dis Markers
europepmc   +1 more source

Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy. [PDF]

J Transl Med
Chen Q, Chen T, Gan L, Lu Y, Qian B.
europepmc   +1 more source

Challenging Cases in Urothelial Cancer

Bladder Cancer, 2016
Mark S. Soloway
doaj   +1 more source

Computational pathology in bladder cancer: A scoping review. [PDF]

Bladder Cancer
Superdock M, Wobker SE, Carmicheal I, Kim WY.   +3 more
europepmc   +1 more source